Towards Precision Medicine for Diabetes in Pregnancy

Launched by ZUYDERLAND MEDISCH CENTRUM · Jun 27, 2023

Keywords

ClinConnect Summary

This clinical trial, called "Towards Precision Medicine for Diabetes in Pregnancy," is focused on understanding how different types of gestational diabetes (diabetes that develops during pregnancy) respond to treatment with metformin, a common medication. The researchers want to see if the effectiveness of metformin varies for women whose gestational diabetes is caused by insulin resistance (when the body doesn't use insulin well) versus those whose condition is due to low insulin production. By studying 103 women with gestational diabetes, they aim to find better, more personalized treatment options instead of a one-size-fits-all approach.

To be eligible for this study, participants need to be women who are at least 20 weeks pregnant and have been diagnosed with gestational diabetes, for which they are receiving metformin. Unfortunately, women with pre-existing diabetes, high blood pressure, or those who smoke or use certain medications that could affect the study’s results won't be able to participate. Throughout the trial, participants will be monitored closely to assess their blood sugar levels and overall health, as well as the health of their babies, to gather important information that could improve future care for gestational diabetes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • having a confirmed single, viable pregnancy past 20 weeks gestation.
• • assigned to pharmacological (ie metformin) treatment for GDM.
• Exclusion Criteria:
• • pre-existing diabetes, hypertension (SBP \>160 mmHg \& DBP \>110 mmHg)
• • using medication related to study outcomes prior to GDM diagnosis (insulin, metformin, glyburide, systemic steroids, mood stabilizers, ADHD medication)
• • smoking or using recreational drugs that may affect pregnancy outcomes